trending Market Intelligence /marketintelligence/en/news-insights/trending/eois4mi2qle3vybeead79a2 content esgSubNav
In This List

Valeant upsizes loan agreement; to borrow $4.57B

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Valeant upsizes loan agreement; to borrow $4.57B

Valeant Pharmaceuticals International Inc. said it upsized its previously announced refinancing agreement, now looking to borrow $4.57 billion in new term B loans as opposed to $3.82 billion originally.

The Canadian drugmaker added that one of its business units launched an offering of $750 million worth of unsecured senior notes due 2027.

The new loans will be used to refinance Valeant's outstanding term B loans and redeem its senior notes.